Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
FibroGen Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
FGEN
Nasdaq
8731
https://www.fibrogen.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for FibroGen Inc
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
- Aug 31st, 2023 2:15 pm
FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%
- Aug 30th, 2023 3:09 pm
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
- Aug 29th, 2023 8:15 pm
Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround
- Aug 16th, 2023 1:35 pm
Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation?
- Aug 9th, 2023 1:14 pm
Q2 2023 FibroGen Inc Earnings Call
- Aug 8th, 2023 2:08 pm
FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- Aug 7th, 2023 11:30 pm
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
- Aug 7th, 2023 9:40 pm
FibroGen Reports Second Quarter 2023 Financial Results
- Aug 7th, 2023 8:01 pm
FibroGen Announces Leadership Transition
- Jul 25th, 2023 11:00 am
FibroGen to Report Second Quarter 2023 Financial Results
- Jul 24th, 2023 11:00 am
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
- Jul 21st, 2023 11:17 am
FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- Jul 14th, 2023 1:55 pm
Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround
- Jul 11th, 2023 1:35 pm
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
- Jul 1st, 2023 12:46 pm
FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study
- Jun 27th, 2023 4:45 pm
FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug
- Jun 26th, 2023 8:04 pm
FibroGen, Inc.'s (NASDAQ:FGEN) institutional investors lost 4.0% last week but have benefitted from longer-term gains
- Jun 26th, 2023 3:34 pm
UPDATE 2-FibroGen's drug fails late-stage trial for treating lung disease
- Jun 26th, 2023 11:22 am
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
- Jun 26th, 2023 11:04 am
Scroll